Increased activation of the epidermal growth factor receptor (EGFR) is frequently observed in tumors, and inhibition of the signaling pathways originated in the EGFR normally renders tumor cells more sensitive to apoptotic stimuli. However, we show that inhibition of EGFR signaling in non-transformed breast epithelial cells by EGF deprivation or gefitinib, an inhibitor of EGFR tyrosine kinase, causes the upregulation of the long isoform of caspase-8 inhibitor FLICE-inhibitory protein (FLIP L ) and makes these cells more resistant to the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). We demonstrate that the extracellular signal-regulated kinase (ERK)1/2 pathway plays a pivotal role in the regulation of FLIP L levels and sensitivity to TRAIL-induced apoptosis by EGF. Upregulation of FLIP L upon EGF deprivation correlates with a decrease in c-Myc levels and c-Myc knockdown by siRNA induces FLIP L expression. FLIP L upregulation and resistance to TRAIL in EGF-deprived cells are reversed following activation of an estrogen activatable form of c-Myc (c-Myc-ER). Finally, constitutive activation of the ERK1/2 pathway in HER2/ERBB2-transformed cells prevents EGF deprivation-induced FLIP L upregulation and TRAIL resistance. Collectively, our results suggest that a regulated ERK1/2 pathway is crucial to control FLIP L levels and sensitivity to TRAIL in non-transformed cells, and this mechanism may explain the increased sensitivity of tumor cells to TRAIL, in which the ERK1/2 pathway is frequently deregulated.
Increased activation of the epidermal growth factor receptor (EGFR) is frequently observed in tumors, and inhibition of the signaling pathways originated in the EGFR normally renders tumor cells more sensitive to apoptotic stimuli. However, we show that inhibition of EGFR signaling in non-transformed breast epithelial cells by EGF deprivation or gefitinib, an inhibitor of EGFR tyrosine kinase, causes the upregulation of the long isoform of caspase-8 inhibitor FLICE-inhibitory protein (FLIP L ) and makes these cells more resistant to the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). We demonstrate that the extracellular signal-regulated kinase (ERK)1/2 pathway plays a pivotal role in the regulation of FLIP L levels and sensitivity to TRAIL-induced apoptosis by EGF. Upregulation of FLIP L upon EGF deprivation correlates with a decrease in c-Myc levels and c-Myc knockdown by siRNA induces FLIP L expression. FLIP L upregulation and resistance to TRAIL in EGF-deprived cells are reversed following activation of an estrogen activatable form of c-Myc (c-Myc-ER). Finally, constitutive activation of the ERK1/2 pathway in HER2/ERBB2-transformed cells prevents EGF deprivation-induced FLIP L upregulation and TRAIL resistance. Collectively, our results suggest that a regulated ERK1/2 pathway is crucial to control FLIP L levels and sensitivity to TRAIL in non-transformed cells, and this mechanism may explain the increased sensitivity of tumor cells to TRAIL, in which the ERK1/2 pathway is frequently deregulated. Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a ligand of the TNF family capable of inducing apoptosis in a wide variety of cancer cells upon binding to pro-apoptotic receptors, but with no effect in the majority of normal human cells tested. 1 This unique characteristic of TRAIL is currently being exploited as a potential antitumor therapy. 2 Activation of TRAIL receptors (TRAIL-Rs) leads to the formation of the death-inducing signaling complex (DISC), which includes the receptor itself, the adapter molecule Fas-associated death domain (FADD) and procaspase-8. 3, 4 Processing and activation of caspase-8 at the DISC leads to a cascade of apoptotic events resulting in cell death. At the DISC level, the apoptotic signal may be inhibited by cellular FLICE-inhibitory protein (cFLIP), the homolog of viral FLIP (vFLIP) in vertebrate cells. 5 In most cells, cFLIP exists as two alternative spliced isoforms: FLIP L , a homolog of caspase-8 that lacks critical amino acids for proteolytic caspase activity, and cFLIP S , consisting only of two death effector domains (DED). 5 Although the role of FLIP L as an inhibitor of apoptotic signaling has been controversial, 6, 7 recent data indicate that heterodimerization of FLIP L with procaspase-8 induces limited caspase-8 activation, preventing further transduction of the apoptotic signal. 8 FLIP expression fluctuates in a cell-type-specific manner and in response to various stimuli, transcriptionally through the NF-kB pathway, 9 and at the protein level via altered rates of proteasomal degradation, 10 which makes it a versatile inhibitor of apoptotic responses mediated by death receptors.
Binding of epidermal growth factor (EGF) to its monomeric receptor (EGFR) activates homo/heterodimerization and selfphosphorylation on tyrosine residues, which are used by docking proteins to engage molecules involved in different signaling pathways. 11 Activation of the Ras-dependent extracellular signal-regulated kinase (ERK)1/2 mitogen-activated protein kinase (MAPK) pathway by EGF in normal cells is required for efficient G 1 -to S-phase transition and for the control of cell proliferation. 12 Upon activation, ERK1/2 translocates to the nucleus and phosphorylates the ternary complex factor, which in turn induces the transcription of immediate-early genes like c-Fos and c-Myc. 13, 14 Prolonged ERK activation results in c-fos and c-myc phosphorylation, stabilizing these transcription factors and thereby promoting activation of the G 1 -specific cyclin-dependent kinases and cell cycle entry. 15, 16 In many human cancers, including breast carcinoma, EGFR overexpression is correlated with cellular proliferation, angiogenesis and tumor growth, leading to invasiveness and metastasis, 17 thus providing a potential target for therapy. 18 In several tumor cell types, activation of the EGFR induces resistance to different apoptotic stimuli, including TRAIL, 19 due to activation of the phosphatidyl inositol 3-kinase (PI3K)/ AKT pathway. However, despite all the available evidences in tumor cells, the regulation of TRAIL sensitivity by EGFR signaling in non-tumor cells remains to be investigated. We report here that EGFR activation downregulates cFLIP expression and enhances the sensitivity of non-transformed human breast epithelial cells to TRAIL-induced apoptosis.
Our results also indicate that cFLIP levels and TRAIL sensitivity are both controlled by the EGFR-mediated regulation of the ERK1/2 pathway and c-myc expression. In addition, we show that deregulated ERK1/2 activation in human breast epithelial cells transformed with the oncogene Her2/ERBB2 prevents EGF deprivation-induced FLIP L upregulation and TRAIL resistance, underlining the relevance of this pathway in controlling TRAIL-induced apoptosis.
Results
EGF controls the sensitivity of human breast epithelial cells to TRAIL-promoted apoptosis at the apical level in TRAIL-R signaling. In the past years, several compounds targeting the EGFR have been developed to treat advanced cancers. 18 Moreover, inhibition of EGFR signaling synergizes with TRAIL in the induction of apoptosis in tumor cells. 20 However, cross-talk between EGFR and TRAIL-R signaling has not been investigated in non-tumor cells.
To address this issue, we determined the effect of EGF deprivation on the apoptotic response to TRAIL in non-tumor breast epithelial cell lines. Results depicted in Figure 1a and Supplementary Figure S1A and S1C demonstrate that preventing EGFR signaling by EGF deprivation induced resistance to TRAIL. These results we confirmed with gefitinib, an inhibitor of the EGFR tyrosine kinase and EGFR signaling. 21 Incubation of MCF10A cells in EGF-containing medium (CM) with gefitinib completely inhibited TRAILinduced apoptosis (Supplementary Figure S2A) , further indicating that EGFR activation facilitates TRAIL-induced apoptosis in non-tumor cells.
Activation of pro-apoptotic receptors by TRAIL induces apical procaspase-8 cleavage to generate the small subunit, p12, and the p43/41 intermediate fragment, which is subsequently processed to produce the large catalytically active p18 subunit. 4 We determined the processing of procaspase-8 in MCF10A cells treated with TRAIL following culture of cells in the presence or absence of EGF. Procaspase-8 cleavage to generate its 43-41 kDa intermediate fragments, and the subsequent generation of p18 subunit upon TRAIL-R activation were markedly inhibited in MCF10A cells deprived of EGF (Figure 1b) . Figure S2B) , confirming that EGFR activation by EGF is involved in the regulation of FLIP L levels in non-transformed breast epithelial cells. In contrast, deprivation of either insulin or hydrocortisone, two medium additives for optimal growth of MCF10A cells, 22 did not upregulate FLIP L expression (Supplementary Figure S2C) .
Time-course analysis of FLIP L levels following EGF deprivation (Figure 2a , left panel) indicated that FLIP L , but not FLIP S , markedly accumulated in MCF10A cells between 40 and 72 h after EGF removal. FLIP L levels slightly increased after 72 h incubation in the presence of EGF (Figure 2a , right panel), which was associated to a reduction in EGFR signaling as determined by the inhibition of ERK1/2 phosphorylation, most likely reflecting the impact of cell density on EGFR signaling as reported recently. 23 We next determined whether the upregulation of FLIP L protein seen in EGFdeprived cells was also observed at the mRNA level. RT-qPCR analysis of mRNA levels demonstrated that EGF deprivation induced a marked upregulation of FLIP L mRNA starting at 40 h after EGF withdrawal (Figure 2b ). Strikingly, a strong correlation was observed between the decrease in EGFR signaling (ERK1/2 phosphorylation) and the increased expression of FLIP L and resistance of MCF10A cells to TRAIL following EGF deprivation (Figures 2a and c) .
As FLIP L levels are important determinants of the sensitivity of breast tumor and non-tumor epithelial cells to TRAILinduced apoptosis, 24, 25 we then assessed whether silencing Role of the ERK1/2 pathway in the control of FLIP L levels and TRAIL resistance in breast epithelial cells. Upon EGFR activation by EGF, the MAPK/ERK and the PI3K/Akt pathways, among others, are activated to produce a physiological outcome. 11 To investigate the role of these Following puromycin selection for stably infected cell lines, cells were treated with soluble TRAIL (500 ng/ml) for 6h in the presence of EGF. Apoptosis was measured as in Figure 1 . Error bars represent S.D. from three independent experiments. ***Po0.001. FLIP L levels were assessed by western blotting and GAPDH was used as a protein loading control Figure  S2D) . Downregulation of FLIP L after re-addition of CM to EGF-deprived cells was not blocked by LY294002 (Figure 4a ), although AKT was significantly inhibited, which indicated that the PI3K/Akt pathway was not involved in FLIP L regulation by EGFR signaling in MCF10A cells. In contrast to the lack of involvement of the PI3K/Akt pathway in the regulation of FLIP L expression by EGF, the results depicted in Figure 4b To further demonstrate the role of the ERK1/2 pathway in EGFR-mediated regulation of FLIP L expression, we generated MCF10A cells overexpressing a constitutively active form of MEK1 (CAMEK1). As compared to mocktransfected cells, CAMEK1 cells maintained ERK1/2 phosphorylation after 48 h in the absence of EGF (Figure 5a ). Interestingly, EGF deprivation did not result in the upregulation of FLIP L in CAMEK1 cells, further supporting an inhibitory role of the ERK1/2 pathway in the regulation of FLIP L expression. Finally, we examined whether the EGFRmediated regulation of sensitivity to TRAIL was altered in cells stably overexpressing CAMEK1. As shown in Figure 5b Role of c-myc in the control of FLIP L levels in MCF10A cells by EGF. C-myc is a member of the Myc family of transcription factors that plays a central role in regulating cell growth, cell-cycle progression and apoptosis. 27 C-myc is regulated at both transcriptional and post-transcriptional levels by the ERK1/2 pathway following activation of growth factors receptors. 16, 28 It has also been reported that c-myc could repress FLIP expression at the transcriptional level. 29 To determine the role of c-myc in EGFR-mediated downregulation of FLIP L and sensitization to TRAIL-induced apoptosis, we first examined the regulation by EGF of c-myc protein levels in MCF10A cells. Results shown in Figure 6a indicate that EGF deprivation resulted in the inhibition of the ERK1/2 pathway and c-myc downregulation. Moreover, re-addition of EGF to EGF-deprived cells triggered the activation of the ERK1/2 pathway and the upregulation of c-myc in an ERK1/2-dependent manner, both events following an opposite pattern to FLIP L levels. To further investigate the role of c-myc in the regulation of FLIP L levels by EGF, we examined whether silencing c-myc expression could have an impact on FLIP L levels in cells maintained in EGF-CM. Results shown in Figure 6b indicate that c-myc knockdown induced the expression of both FLIP L mRNA (left panel) and protein (right panel) in cells grown in the presence of EGF.
As a complementary approach to further demonstrate the role of c-myc in controlling FLIP L expression in EGF-deprived cells, we generated MCF10A cells constitutively expressing an Myc-ER chimera. 30 In these cells, activity of the chimeric myc protein is completely dependent on the addition of exogenous 4-hydroxytamoxifen (4HT). 31 As a positive control of Myc-ER activation, we determined E2F-1 expression, a transcription factor positively regulated by c-myc, 32 in cells treated with 4HT. As shown in Figure 6c , E2F-1 was upregulated following Myc-ER activation by 4HT in EGFdeprived cells. Interestingly, Myc-ER activation resulted in FLIP L downregulation in MCF10A cells deprived of EGF, at both the protein and mRNA levels (Figure 6c) . Finally, we analyzed the sensitivity to TRAIL-induced apoptosis in cells in which Myc-ER was activated by 4HT. Results shown in Figure 6d demonstrate that Myc-ER activation was sufficient to sensitize EGF-deprived cells to TRAIL.
Transformation blocks FLIP L upregulation and TRAIL resistance upon EGF deprivation in MCF10A cells: role of the ERK1/2 pathway. To investigate the impact of cell transformation on the regulation of FLIP L expression and TRAIL sensitivity by EGF, we generated MCF10A cells that expressed a constitutively active form of the oncogene ERBB2/HER-2/neu. 33 In cells overexpressing the ERBB2 (NeuT) protein, the ERK1/2 pathway was not inhibited upon EGF withdrawal (Figure 7a 
Discussion
Preclinical studies conducted in the past years have demonstrated that TRAIL as well as agonistic antibodies against TRAIL-R1 and TRAIL-R2 can efficiently induce apoptosis in tumor cells, but not in the majority of normal cells. 34, 35 In many of these preclinical studies, TRAIL-sensitive cell lines were used and it has since become clear that some primary tumor cells are TRAIL resistant. 36 Moreover, it has been reported that EGFR pathway activation limits TRAIL-induced apoptosis in breast tumor cells 19 and the small-molecule EGFR inhibitor gefitinib reverses TRAIL resistance in other tumor cells. 20 In this respect, there are ongoing clinical trials using combination of EGFR inhibitors and recombinant TRAIL. 37 However, it is rather unknown the effect that these combination treatments may have in non-tumor cells. In our study, we demonstrate for the first time that preventing EGFR signaling induces resistance to TRAIL in non-tumor breast epithelial cells through the upregulation of FLIP L and inhibition of TRAILinduced apical caspase-8 activation.
Our recently published data demonstrate that FLIP L knockdown activates apoptosis by endogenous TRAIL in a DISC-dependent manner in the presence of EGF and reduces the number of acini in 3D basement-membrane cultures of MCF10A cells. 25 Conversely, FLIP L overexpression in MCF10A cells delays lumen formation in these cultures. 25 In this respect, it has been reported that TRAIL is upregulated during morphogenesis of MCF10A mammary epithelial cells in 3D cultures and cooperates with Bcl-2 family proteins to regulate lumen formation in MCF10A acini. 38 During morphogenesis, the cells in the center of the epithelial mass lack matrix attachment, which leads to inhibition of EGFR signaling. 26 In accordance with our results, it would be predicted that loss of EGFR signaling in the inner cells of the acini would induce FLIP L expression and inhibit TRAIL-induced cell death. Collectively, these results suggest that maintenance of elevated FLIP L levels may have an important role in the timely control of morphogenesis in the mammary gland by preventing the early activation of TRAIL-induced cell death.
Of the signaling pathways activated upon engagement of tyrosine kinase receptors by their ligands, two of them, the PI3K/Akt and the MAPK/ERK pathways, are frequently reported to play a survival role preventing the induction of apoptosis. 19, 39 Furthermore, inhibition of PI3K/Akt 40 or MAPK/ERK 41 increases the sensitivity of tumor cells to TRAIL-induced apoptosis. In contrast, other studies have shown that sensitivity to TRAIL can be enhanced upon activation of the PI3K/Akt 42 or ERK1/2 43 pathways, although the underlying mechanisms have not been characterized. We hereby report for the first time that in non-tumor human breast epithelial cells, activation of the ERK1/2 MAPK pathway by EGF is crucially involved in the sensitization of these cells to TRAIL-induced apoptosis. Most of the studies examining the regulation of TRAIL sensitivity by the PI3K/Akt and MAPK/ ERK pathways have been carried out in tumor cell lines of different sources in which these signaling pathways are commonly deregulated, leading to aberrant activation of genes involved in cell survival, metabolism, proliferation and migration. 44 Moreover, it is well known that the number of active cell surface receptors for growth factors can determine whether ERK activation is transient or sustained, which results in markedly different cellular responses. 45 Therefore, differences in cell surface EGFR levels may explain the different outcome of EGFR activation on FLIP levels and apoptosis sensitivity between normal and tumor cells.
Our results are in agreement with previous data indicating that sensitivity of EGF-dependent non-tumor breast epithelial cells to different apoptotic stimuli, including death receptor ligands, is abrogated in three-dimensional cultures (3D). 46 In these 3D cultures, formation of a polarized structure is achieved and activation of the MAPK/ERK pathway by EGF is markedly attenuated. 46, 47 Whether or not FLIP L levels increase in 3D cultures need to be investigated. Interestingly, non-polarized malignant breast epithelial cells maintain an elevated MAPK/ERK pathway activation in response to ERK1/2 controls FLIP L levels and TRAIL resistance R Yerbes et al EGF 47 and remain sensitive to death receptor ligands in 3D cultures. 46 Through the phosphorylation of both cytoplasmic signaling proteins and transcription factors, activated ERK1/2 regulates cell metabolism, survival, differentiation, proliferation and migration. Among the transcription factors regulated by ERK, the ternary complex factor plays an important role in inducing the expression of immediate-early genes such as c-Fos and c-Myc. 48 In addition, activation of the ERK1/2 pathway induces stabilization of the c-myc protein. 49 Interestingly, our data demonstrate that EGF-dependent activation of the ERK1/2 pathway enhances c-Myc levels and negatively regulates FLIP L expression in breast epithelial cells, and sensitizes these cells to TRAIL-induced apoptosis. By using either siRNA oligonucleotides to downregulate c-myc or the estrogen activatable Myc-ER chimera, we have provided further evidences supporting that c-myc plays a regulatory role in the control of FLIP L levels by EGF, which are in agreement with previous data indicating that c-myc binds and represses the human FLIP promoter and sensitizes cells to TRAIL. 29 However, in tumor cells c-myc expression is frequently dissociated from the ERK1/2 pathway, either by mutation, reduced degradation through the ubiquitinproteasome system or by other mechanisms. 49, 50 Accordingly, in tumor cells FLIP L levels could be regulated in an ERK1/2-independent manner by other survival pathways. 51 Our results also indicate that in EGF-deprived cells, c-myc activation using a 4HT-activatable Myc-ER chimera does not completely reproduce the sensitization achieved by EGF re-addition, which suggests that other effectors downstream of ERK1/2 activation could be also important for a complete apoptotic response to TRAIL. In this respect, it has been reported that c-Fos can function as a proapoptotic protein by repressing the expression of FLIP L through binding to the gene promoter. 52 Alternatively, other signaling emerging from the EGFR such as the p38-MAPK and the Jun N-terminal kinase (JNK) pathways might downregulate FLIP L expression by transcriptional and post-transcriptional mechanisms. Thus, it has been demonstrated that EGFR-mediated activation of the p38 pathway regulates the activity of the transcription factor SP3, 53 which under certain conditions could be a negative regulator of the FLIP L gene promoter. 54 Moreover, JNK activation by TNF-a reduces FLIP L stability by a mechanism involving the JNK-mediated phosphorylation and activation of the E3 ubiquitin ligase Itch, which ubiquitinates FLIP L and induces its proteasomal degradation. 55 Overexpression of oncogenic receptor tyrosine kinases is a common event in breast cancer. In particular, 15-30% of all cases show elevated ERBB2, 56 but despite the development of ERBB2/HER2-targeted therapies, only 35% of ERBB2-positive patients initially respond to those treatments. It has been shown in experiments in vitro 40 and in vivo 57 that combination of antibodies against ERBB2 and TRAIL receptors facilitates apoptosis and tumor regression, although there are data reporting that the apoptosis-inducing capacity of these combinations is cell type-dependent. 58 Our results indicate that in ERBB2-overexpressing cells sensitivity to TRAIL is controlled by the ERK1/2 pathway-mediated regulation of FLIP L levels. These data suggest that amplification of ERBB2 in tumor cells may have different outcomes regarding sensitivity to TRAIL. On one hand, it may increase resistance to TRAIL through ERBB2-induced activation of the PI3K/Akt pathway. 40 On the other hand, it may contribute to maintain low FLIP L levels by ERK1/2-mediated activation of c-myc and other genes, 29, 52 which may result in enhanced sensitivity to TRAIL. This is not unique of ERBB2 as other oncoproteins could also sensitize cells to TRAIL by activating the ERK1/2 pathway, 59 although the mechanism underlying this sensitization has not been elucidated. Our data highlight the role of the EGF-regulated, ERK1/2 pathway-mediated regulation of FLIP L levels as an important mechanism modulating the sensitivity of human breast epithelial cells to TRAIL-induced apoptosis that may contribute, in concert with others, to the differential sensitivity of normal and tumor cells to TRAIL. At the same time, our results provide arguments for a cautious clinical application of TRAIL in cancer patients, especially in combination with agents that may inhibit the ERK1/2 pathway.
Materials and Methods
Reagents and antibodies. Recombinant human EGF was from Peprotech (London, UK). Recombinant human TRAIL (residues 95-281) was produced as described previously.
60 U0126 and gefitinib were purchased from Selleck Chemicals (Houston, TX, USA). Mouse anti-a-tubulin antibody, LY294002, 4HT, hydrocortisone, transferrin and puromycin were obtained from Sigma-Aldrich (St. Louis, MO, USA). Anti-caspase-8 was generously provided by Dr. Gerald Cohen (Leicester University, Leicester, UK). Anti-FADD, anti-ERBB2 and anti-E2F1 monoclonal antibodies were obtained from BD Biosciences (Erembodegem, Belgium). GAPDH and c-myc monoclonal antibodies were from Santa Cruz Technology (Santa Cruz, CA, USA). Anti-TRAIL-R2 and anti-c-FLIP monoclonal antibody (NF6) were from Alexis Corporation (Lausen, Switzerland). Anti-TRAIL-R1 and anti-TRAIL-R2 monoclonal antibodies for surface receptor analysis were from Abcam (Cambridge, UK). Anti-pAKT, anti-AKT, anti-pERK1/2 and anti-MEK1 antibodies were obtained from Cell Signaling Technology (Temecula, CA, USA). Anti-ERK antibody was from Upstate-Millipore (New York, NY, USA). Anti-Bim polyclonal antibody was purchased from Calbiochem (Darmstadt, Germany). Horseradish peroxidase or FITC-conjugated secondary antibodies, goat antimouse and goat anti-rabbit were obtained from DAKO (Cambridge, UK).
Cell lines. MCF10A and MCF12A cell lines were maintained in DMEM/F12 supplemented with 5% donor horse serum, 2 mM L-glutamine, 20 ng of EGF per ml, 10 mg of insulin per ml, 100 ng of cholera toxin per ml, 0.5 mg of hydrocortisone per ml, 50 U of penicillin per ml and 50 mg of streptomycin per ml at 37 1C in a 5% CO 2 -humidified, 95% air incubator. The 184A1 cells were cultured in the same medium with transferrin (5 mg/ml).
Determination of apoptosis. Cells (3 Â 10 5 per well) were treated in 6-well plates as indicated in the figure legends. After treatment, hypodiploid apoptotic cells were detected by flow cytometry according to published procedures. 60 Basically, cells were washed with phosphate-buffered saline (PBS), fixed in cold 70% ethanol and then stained with propidium iodide while treating with RNAse. Quantitative analysis of sub-G1 cells was carried out in a FACSCalibur cytometer using the Cell Quest software (Becton Dickinson, Mountain View, CA, USA).
Immunoblot analysis of proteins. Cells (3 Â 10 5 ) were washed with PBS and protein content was measured following cell lysis using the Bradford reagent (Bio-Rad Laboratories, Hercules, CA, USA) before adding Laemmli sample buffer. Where indicated, whole cell extracts were obtained. Samples were sonicated, and proteins were resolved on SDS-polyacrylamide minigels and detected as described previously. 60 Analysis of TRAIL receptors by flow cytometry. MCF10A cells were detached with RPMI/3 mM EDTA, and cytofluorimetric analysis of proteins was performed as described previously. 60 Briefly, cells were washed in ice-cold PBS, and resuspended in PBS. Cells were then labeled with anti-TRAIL receptor antibodies (5 mg/ml) or no antibody (negative control) and then incubated with goat ERK1/2 controls FLIP L levels and TRAIL resistanceanti-mouse FITC-conjugated antibody (F(ab) 2 fragment). Labeled cells were analyzed by flow cytometry using the Cell Quest software.
Real-time RT-PCR. Total RNA was isolated from MCF10A cells with the Trizol reagent (Life Technologies, Grand Island, NY, USA) as recommended by the supplier. Total RNA (2 mg) was used as a template for cDNA synthesis using an RT-PCR kit (Perkin-Elmer, Waltham, MA, USA). mRNA expression was analyzed in triplicate by quantitative RT-PCR on the ABI Prism7500 sequence detection system using predesigned Assay-on-demand primers and probes (Applied Biosystems, Carlsbad, CA, USA). mRNA expression was determined by the comparative cycle threshold (C t ) method (DDC t ). Hypoxanthine-guanine phosphoribosyltransferase (HPRT Part Number 4331182 and HPRT1 Part Number 4351370) was used as an internal control and mRNA expression levels of FLIP L and cFLIP S were given as fraction of mRNA levels in control cells. RNA interference. siRNAs against FLIP L : 5 0 -CCUAGGAAUCUGCCUGAU AdTdT-3 0 and non-targeting scrambled siRNA were synthesized by Sigma Proligo (St. Louis, MO, USA). siRNA against c-Myc was purchased from Qiagen (Germantown, PA, USA) (FlexiTube). Cells were transfected with 50 nM siRNAs using DharmaFECT-1 (Dharmacon, Lafayette, CA, USA) as described by the manufacturer. After 24 h for FLIP L siRNA or 48 h for c-myc siRNA, transfection medium was replaced with regular medium before further analysis. Statistical Analysis. All data are presented as the mean ± S.D. of at least three independent experiments. The differences among different groups were determined by the Student's t-test. Po0.05 was considered significant.
